Matinas BioPharma Earnings Estimate
| MTNB Stock | USD 0.67 0.01 1.47% |
Matinas BioPharma Earnings per Share Projection vs Actual
About Matinas BioPharma Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Matinas BioPharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Matinas BioPharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Matinas BioPharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -179.8 M | -170.8 M | |
| Retained Earnings Total Equity | -137.4 M | -130.5 M | |
| Earnings Yield | (11.24) | (10.68) | |
| Price Earnings Ratio | (0.09) | (0.10) | |
| Price Earnings To Growth Ratio | 0.02 | 0.02 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Matinas BioPharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Matinas BioPharma. Expected growth trajectory for Matinas significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Matinas BioPharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Matinas BioPharma requires distinguishing between market price and book value, where the latter reflects Matinas's accounting equity. The concept of intrinsic value—what Matinas BioPharma's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Matinas BioPharma's price substantially above or below its fundamental value.
Understanding that Matinas BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Matinas BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Matinas BioPharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.